DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)
South Korea · Delayed Price · Currency is KRW 4,270.00
-80.00 (-1.84%)
At close: May 29, 2026
DongKoo Bio & Pharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 229,737 | 230,348 | 248,515 | 215,064 | 194,496 | 155,131 |
Other Revenue | 12,339 | 12,339 | 760.23 | 622 | 491.86 | 17.86 |
| 242,076 | 242,688 | 249,275 | 215,686 | 194,988 | 155,149 | |
Revenue Growth (YoY) | -0.68% | -2.64% | 15.57% | 10.62% | 25.68% | 11.45% |
Cost of Revenue | 99,125 | 98,346 | 97,388 | 83,610 | 77,128 | 62,812 |
Gross Profit | 142,951 | 144,342 | 151,887 | 132,076 | 117,860 | 92,337 |
Selling, General & Admin | 121,405 | 122,906 | 129,715 | 105,675 | 91,394 | 72,852 |
Research & Development | 11,467 | 10,790 | 8,380 | 10,752 | 8,258 | 10,114 |
Amortization of Goodwill & Intangibles | 184.35 | 185.43 | 182.86 | 144.88 | 124.77 | 109.81 |
Other Operating Expenses | 308.36 | 292.07 | 375.81 | 203.67 | 273.54 | 282.42 |
Operating Expenses | 134,229 | 135,095 | 139,197 | 117,460 | 101,023 | 84,198 |
Operating Income | 8,722 | 9,248 | 12,691 | 14,616 | 16,836 | 8,139 |
Interest Expense | -3,630 | -3,509 | -2,894 | -1,760 | -1,039 | -415.63 |
Interest & Investment Income | 143.28 | 176.76 | 224.42 | 310.5 | 179.43 | 50.88 |
Currency Exchange Gain (Loss) | 227.46 | 71.22 | 93.19 | 20.79 | 30.37 | 101.41 |
Other Non Operating Income (Expenses) | 12,123 | 16,447 | 505.2 | 287.04 | 956.37 | 4,102 |
EBT Excluding Unusual Items | 17,586 | 22,434 | 10,619 | 13,474 | 16,963 | 11,978 |
Gain (Loss) on Sale of Investments | 55,134 | 52,550 | -10,584 | 2,881 | 4,501 | 1,827 |
Gain (Loss) on Sale of Assets | 1,893 | 1,023 | 7,114 | 401.74 | 136.72 | 2,258 |
Asset Writedown | -12,855 | -14,595 | -3,331 | -2,016 | -13,685 | -4,728 |
Pretax Income | 61,758 | 61,413 | 3,819 | 14,741 | 7,916 | 11,333 |
Income Tax Expense | 11,443 | 11,240 | 1,828 | 2,932 | 1,302 | 2,007 |
Earnings From Continuing Operations | 50,315 | 50,172 | 1,991 | 11,808 | 6,614 | 9,327 |
Minority Interest in Earnings | 60.91 | 100.1 | 44.78 | 3.17 | - | - |
Net Income | 50,376 | 50,272 | 2,036 | 11,812 | 6,614 | 9,327 |
Net Income to Common | 50,376 | 50,272 | 2,036 | 11,812 | 6,614 | 9,327 |
Net Income Growth | - | 2369.74% | -82.77% | 78.59% | -29.09% | 2.04% |
Shares Outstanding (Basic) | 27 | 27 | 27 | 28 | 28 | 28 |
Shares Outstanding (Diluted) | 29 | 28 | 27 | 28 | 28 | 28 |
Shares Change (YoY) | 5.42% | 3.59% | -1.74% | -0.48% | -1.78% | -0.12% |
EPS (Basic) | 1858.50 | 1859.04 | 75.00 | 427.63 | 238.29 | 330.05 |
EPS (Diluted) | 1769.06 | 1791.00 | 75.00 | 427.63 | 238.29 | 330.05 |
EPS Growth | - | 2288.00% | -82.46% | 79.46% | -27.80% | 2.16% |
Free Cash Flow | -9,769 | -21,944 | -4,522 | -10,260 | 11,841 | 13,637 |
Free Cash Flow Per Share | -342.53 | -780.52 | -166.62 | -371.44 | 426.63 | 482.57 |
Gross Margin | 59.05% | 59.48% | 60.93% | 61.23% | 60.45% | 59.51% |
Operating Margin | 3.60% | 3.81% | 5.09% | 6.78% | 8.63% | 5.25% |
Profit Margin | 20.81% | 20.71% | 0.82% | 5.48% | 3.39% | 6.01% |
Free Cash Flow Margin | -4.04% | -9.04% | -1.81% | -4.76% | 6.07% | 8.79% |
EBITDA | 17,415 | 18,166 | 19,964 | 20,644 | 22,469 | 13,193 |
EBITDA Margin | 7.19% | 7.49% | 8.01% | 9.57% | 11.52% | 8.50% |
D&A For EBITDA | 8,693 | 8,919 | 7,274 | 6,028 | 5,632 | 5,054 |
EBIT | 8,722 | 9,248 | 12,691 | 14,616 | 16,836 | 8,139 |
EBIT Margin | 3.60% | 3.81% | 5.09% | 6.78% | 8.63% | 5.25% |
Effective Tax Rate | 18.53% | 18.30% | 47.87% | 19.89% | 16.44% | 17.71% |
Advertising Expenses | - | 1,820 | 2,848 | 1,595 | 1,630 | 1,971 |